Send us a text In this episode of WTR Small-Cap Spotlight, host Tim Gerdeman and analyst Robert Sassoon speak with Eric Poma PhD, CEO of Calidi Biotherapeutics Inc (NYSE American: CLDI). The discussion focuses on how Calidi is solving the "delivery problem" in cancer treatment, and specifically how to transport cancer-killing oncolytic viruses systemically through the bloodstream without the body’s immune system neutralizing them before they reach the tumor.
All content for WTR Small-Cap Spotlight is the property of Water Tower Research and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text In this episode of WTR Small-Cap Spotlight, host Tim Gerdeman and analyst Robert Sassoon speak with Eric Poma PhD, CEO of Calidi Biotherapeutics Inc (NYSE American: CLDI). The discussion focuses on how Calidi is solving the "delivery problem" in cancer treatment, and specifically how to transport cancer-killing oncolytic viruses systemically through the bloodstream without the body’s immune system neutralizing them before they reach the tumor.
AGIG Breaking New Ground - Advancing Waste-to-Fuel Strategy on the Houston Ship Channel
WTR Small-Cap Spotlight
9 minutes
3 weeks ago
AGIG Breaking New Ground - Advancing Waste-to-Fuel Strategy on the Houston Ship Channel
Send us a text Join Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer at WTR, and Peter Gastreich, Senior Energy Transition and Sustainability Analyst, as they discuss Peter’s recent report on Abundia Global Impact Group (AGIG) including: 1) AGIG’s waste-to-value approach that redirects materials from landfills and incineration; 2) strategy for converting hard to recycle waste plastics and waste woody biomass into high value fuels and chemicals like sustainable aviation fu...
WTR Small-Cap Spotlight
Send us a text In this episode of WTR Small-Cap Spotlight, host Tim Gerdeman and analyst Robert Sassoon speak with Eric Poma PhD, CEO of Calidi Biotherapeutics Inc (NYSE American: CLDI). The discussion focuses on how Calidi is solving the "delivery problem" in cancer treatment, and specifically how to transport cancer-killing oncolytic viruses systemically through the bloodstream without the body’s immune system neutralizing them before they reach the tumor.
